Bioray Biotech Co (ROCO:7561) LT-Debt-to-Total-Asset: 0.08 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7561 Bioray Biotech Co Ltd ROCO:7561
81 GF Score
Price NT$20.00
GF Value NT$29.52
Valuation Significantly Undervalued
View Full Analysis

What is Bioray Biotech Co LT-Debt-to-Total-Asset?

Bioray Biotech Co ROCO:7561 -2.68% 81 LT-Debt-to-Total-Asset is 0.08 as of Dec. 2025. GuruFocus rates ROCO:7561 with a GF Score™ of 81/100 and a GF Value™ of NT$29.52 (Significantly Undervalued).

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bioray Biotech Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.08.

Bioray Biotech Co's long-term debt to total assets ratio declined from Dec. 2024 (0.15) to Dec. 2025 (0.08). It may suggest that Bioray Biotech Co is progressively becoming less dependent on debt to grow their business.

Bioray Biotech Co  (ROCO:7561) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bioray Biotech Co LT-Debt-to-Total-Asset Related Terms

Bioray Biotech Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Bioray Biotech Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioray Biotech Co LT-Debt-to-Total-Asset Chart

Bioray Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.05 0.13 0.12 0.15 0.08

Bioray Biotech Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.08 0.15 0.08 0.08
ROCO:7561
81GF Score
Bioray Biotech Co Ltd ROCO:7561
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioray Biotech Co LT-Debt-to-Total-Asset Calculation

Bioray Biotech Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=42.833/536.582
=0.08

Bioray Biotech Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=42.833/536.582
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.08 mean?
Bioray Biotech Co (ROCO:7561) has a LT-Debt-to-Total-Asset of 0.08 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bioray Biotech Co and its competitors.
Is Bioray Biotech Co's LT-Debt-to-Total-Asset too high?
Bioray Biotech Co's current LT-Debt-to-Total-Asset is 0.08. Overall, Bioray Biotech Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Bioray Biotech Co's LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bioray Biotech Co and its competitors. Bioray Biotech Co's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.52, compared to a current price of NT$20.00 — trading 32.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. Bioray Biotech Co's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current LT-Debt-to-Total-Asset is 0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?

Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued. The current stock price of NT$20.00 is trading 32.2% below its estimated GF Value™ of NT$29.52. GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.

Key valuation signals for ROCO:7561:

  • LT-Debt-to-Total-Asset: 0.08
  • GF Value™: NT$29.52 vs. price of NT$20.00 (32.2% below fair value)
  • GF Score™: 81/100

No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioray Biotech Co Business Description

Address No. 1, Dali 2nd Road, Southern Science Park, Shanhua District, Tainan, TWN, 90846
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
81GF Score

Get the complete analysis for ROCO:7561

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.00
Price
NT$29.52
GF Value